Shares of Longeveron Inc. (LGVN) soars 85% on Monday morning on update of phase 2a trial evaluating Lomecel-B in mild alzheimer's disease.
LGVN is currently trading at $3.1200, or $1.4300 or 84.6154%, on the Nasdaq. The stock opened its trading at $2.3900 after closing Friday at $1.6900. The stock has traded between $1.6200 and $44.0000 in the past 52-week period.
Longeveron is a clinical stage biotechnology company developing regenerative medicines. The company said it has been accepted for a Featured Research Oral Presentation to present the company's CLEAR MIND Phase 2a study results.
Clear-Mind is a Phase 2a randomized clinical trial evaluating Lomecel-BTM in mild Alzheimer's Disease. In addition to the clinical study results, the company has been accepted for a poster presentation at the 2024 Alzheimer's Association International Conference (AAIC), to be held July 28 - August 1, 2024 in Philadelphia, PA, USA.
"We are extremely excited to share the full study results of our CLEAR-MIND trial at the AAIC meeting this year, and have the opportunity to present at the leading forum for Alzheimer's disease clinical investigation," said Wa'el Hashad, CEO of Longeveron.
For comments and feedback contact: editorial@rttnews.com
Business News